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Background: Bacteria grow as biofilms within CF airways. However, antibiotic susceptibility testing is routinely performed on planktonically-
growing bacteria. This study assessed whether CF patients infected with multiresistant organisms had improved clinical outcomes if given
antibiotics that inhibited their biofilm-grown bacteria.
Methods: 110 patients with pulmonary exacerbations were treated with intravenous antibiotics based on susceptibility testing of planktonically-
growing bacteria. A retrospective analysis was done using bacterial isolates grown from their sputum at exacerbation. Each isolate was grown as a
biofilm and combination antibiotic susceptibility testing was performed. Clinical outcomes in patients treated with biofilm-susceptible antibiotics
were compared to those that were not.
Results: 66 of 110 patients (60%) were treated with antibiotic combinations that inhibited all of their planktonically-grown bacterial isolates,
however, when the same isolates were grown as biofilms, only 24 patients (22%) had all of their biofilm-grown isolates remaining susceptible to
the antibiotics (P=b0.001 ). When patients with at least one biofilm-grown susceptible isolate (n=61) were compared to those with none (n=49),
there was a significant decrease in sputum bacterial density (P=0.02) and length of stay (P=0.04) and a non-significant decrease in treatment
failure. Survival analyses of time to next exacerbation showed non-significant trends favoring patients treated with biofilm-effective antibiotics.
Conclusions: Most patients with CF exacerbations do not receive antibiotics that inhibit all biofilm-grown bacteria from their sputum at
exacerbation. Patients treated with biofilm-effective therapy seemed to have improved clinical outcomes.
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Most adults with cystic fibrosis (CF) suffer from chronic
bacterial airway infections. These infections are almost
impossible to eradicate due to their multi-drug resistant nature.
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doi:10.1016/j.jcf.2008.10.005and selective mutational pressures induced by repeated courses
of antibiotic treatment [1]. The refractory nature of these in-
fections poses a challenge to clinicians when deciding which
combinations of antibiotics to use in the treatment of CF
exacerbations associated with multiresistant bacterial airway
infections.
A bacterial biofilm is defined as a community of micro-
organisms that adhere to a surface, encased within an extra-
cellular polysaccharide matrix [2]. The bacterial cells within the
biofilm communicate by a process known as quorum-sensing in
order to coordinate formation of the biofilm. Biofilm-grown
organisms show increased resistance to antibiotics, either
because of decreased penetration of the antibiotics into thed by Elsevier B.V. All rights reserved.
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specific resistance mechanisms [3–5]. Evidence now exists that
bacteria grow as biofilms within CF airways [6,7] and that these
biofilm-grown bacteria are less susceptible to antibiotics than
planktonically grown bacteria [8–10].
Conventionally, hospital microbiology laboratories have
employed standard culture and susceptibility assays where
individual antibiotics are tested against planktonically grown
bacterial isolates from CF sputum. More recently, combinations
of antibiotics have been tested in vitro against multiresistant
bacteria using antibiotic synergy testing or the multiple com-
bination bactericidal antibiotic testing (MCBT) technique
[11]. However, a randomized, double-blind, controlled trial of
MCBT versus standard culture and susceptibility techniques did
not show improved clinical outcomes in CF exacerbations when
the bacterial isolates were grown in planktonic culture [12].
Given that bacteria in the CF lung may grow as biofilms and
that the biofilm-grown bacteria are susceptible to different
antibiotic combinations than those grown by conventional
means, we hypothesized that growing the bacteria as biofilms
and testing them against combinations of antibiotics may yield
information to support better antibiotic choices against CF lung
infections and result in improved clinical outcomes. The ob-
jective of this study was to retrospectively analyze whether CF
patients treated with antibiotic combinations that inhibited
growth of biofilm-grown bacteria retrieved from their sputa
experienced improved clinical outcomes following a pulmonary
exacerbation compared to those who were treated with anti-
biotics that did not inhibit biofilm-growth of their sputum
bacteria.
2. Methods
A retrospective analysis was done using bacterial isolates
and clinical data from a randomised, controlled trial assessing
outcomes following CF exacerbations in patients treated ac-
cording to combination antibiotic susceptibility testing versus
conventional culture and susceptibility testing [12].
2.1. Study subjects
Patients 12 years and older were included in the trial if they
had a confirmed diagnosis of cystic fibrosis and known chronic
infection with multiresistant Burkholderia cepacia, Pseudo-
monas aeruginosa, Stenotrophomonas maltophilia or Achro-
mobacter xylosoxidans bacteria (at least two sputum cultures
within the past 12 months that had grown these organisms).
Patients were excluded if they were pregnant, unable to produce
sputum, had a history of lung transplantation or had previously
participated in the trial. All enrolled patients signed informed
consent and the ethics committee at each participating hospital
approved the study.
2.2. Study design
Patients were enrolled from 10 sites. Sputum samples were
collected at exacerbation before intravenous antibiotics andfollowing 14 days of therapy. Bacterial isolates from the sputum
were kept frozen from the time of the original trial.
Patients were randomized when they experienced an exa-
cerbation of CF pulmonary symptoms that, in the opinion of the
patient's physician, required intravenous antibiotics. A pul-
monary exacerbation was defined according to the 1994 Cys-
tic Fibrosis Foundation Microbiology and Infectious Disease
Consensus Conference [13] as the presence of at least three of
the following 11 new findings or changes in clinical status
compared to the most recent baseline visit: cough; increased
sputum production, change in appearance of expectorated
sputum, or both; fever (≥38 ° C for at least 4 h in a 24 hour
period) on more than one occasion in the previous week;
weight loss ≥1 kg or 5% of bodyweight associated with
anorexia and decreased dietary intake; school or work ab-
senteeism (due to illness) in the previous week; increased
respiratory rate, increased work of breathing, or both; new
finding on chest examination (e.g. rales, wheezing, crackles);
decreased exercise tolerance; decrease in FEV1 of ≥10% from
previous baseline study within the past 3 months; decrease in
hemoglobin saturation (as measured by oximetry) of ≥10%
from baseline value within the past 3 months; new finding on
chest radiograph.
At exacerbation, the antibiotic combination was selected
based on either conventional antibiotic susceptibility tests of
plankontically-grown bacteria or MCBTsusceptibility results of
planktonically-grown bacteria, depending on which group the
patient was randomized into [12]. Patients received any two
intravenous antibiotics± inhaled tobramycin.
All bacterial isolates from the sputum collected at exacer-
bation were later grown as biofilms. The biofilm-grown bac-
terial isolates were then tested against combinations of
antibiotics using the MCBT technique, including the combina-
tion of antibiotics that the patient had received at the time of
exacerbation.
Clinical outcomes for patients in whom at least one biofilm-
grown isolate was susceptible to the prescribed antibiotic com-
bination were compared to those in whom none of the isolates
were susceptible. Also, patients in whom all biofilm-grown
isolates were susceptible were compared to those in whom at
least one isolate was not susceptible.
Outcomes measured over the 14 day treatment period in-
cluded mean change in sputum bacterial density (measured as
the difference in the sum of all the retrieved isolates from each
sputum), absolute changes in FEV1 and forced vital capacity
(FVC), and changes in dyspnea as measured by the Transitional
Dyspnea Index [14]. Other outcomes included time to next
exacerbation, mean length of hospital stay and proportion of
treatment failures. A treatment failure was defined as: re-
quirement for patient transfer to an intensive care unit, or new
requirement for assisted ventilation, or development of acute
respiratory acidosis (arterial pHb7.30, with arterial pCO2-
48 mm Hg, or unremitting fever N38 °C for 5 days while on
study antibiotic therapy, or other evidence of clinical deteriora-
tion while taking study antibiotics which in the opinion of the
local study physician required urgent administration of alter-
native open-label antibiotics.
Table 1
Baseline characteristics of included patients
At least one
biofilm-grown isolate
susceptible (n=61)
No biofilm-
grown isolates
susceptible (n=49)
Age (SD) 27.2 (7.1) 27.9 (8.7)
Sex (male:female) 27:34 26:23
Body-mass index in kg/m2 (SD) 20.3 (5.0) 22.1 (4.3)
Number of isolates 154 80
Infecting organism
Pseudomonas aeruginosa 34 (56%) 16 (33%)
Burkholderia cepacia complex 13 (21%) 20 (41%)
Achromobacter xylosoxidans 0 (0%) 5(10%)
Stenotrophomonas maltophilia 2 (3%) 1(2%)
P. aeruginosa+B. cepacia 11 (18%) 4 (8%)
P. aeruginosa+A. xylosoxidans 0 (0%) 2 (4%)
P. aeruginosa+S. maltophilia 1 (2%) 0 (0%)
S. maltophilia+A. xylosoxidans 0 (0%) 1 (2%)
Baseline lung function
FEV1 in L (SD) 1.67 (0.69) 1.66 (0.69)
FEV1 % predicted (SD) 48.7 (20.5) 46.6 (18.1)
FVC in L (SD) 2.79 (0.92) 2.78 (0.98)
FEV1/FVC % (SD) 59.2 (11.4) 57.8 (13.8)
Lung function on day of exacerbation
FEV1 in L (SD) 1.50 (0.66) 1.46 (0.62)
FEV1 % predicted (SD) 43.3 (18.1) 40.7 (17.0)
FVC in L (SD) 2.48 (0.91) 2.45 (0.94)
FEV1/FVC % (SD) 58.5 (10.7) 60.5 (11.4)
Oxygen saturation % (SD) 94.4 (3.0) 93.2 (4.8)
SD=standard deviation.
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Bacterial biofilms were grown from each of the bacterial
isolates from the sputum collected at the time of exacerbation
using a modified version of the Calgary biofilm technique [15].
The organism inoculum for the biofilm consisted of 100 uL of a
0.5 MacFarland turbidity standard added to each well of a 96
well, round-bottom microtitre plate with a peg lid (Nunc Inc.,
Roskilde, Denmark). The plates with peg lid were incubated, in
the absence of antibiotics, at 35 °C on a rocking table (Bellco
Glass Inc., Vineland, NJ) for 18–24 h overnight to allow for
bacterial biofilm formation on the pegs.
Microtitre plates containing antibiotics in double (two
intravenous antibiotics) or triple (two intravenous antibiotics
and inhaled tobramycin 300 mg twice daily) combinations were
prepared as previously described [12]. The plate included onewell
containing the combination of antibiotics that the patient received
at the time of exacerbation, and wells that served as growth and
sterility controls (no antibiotics and no organism in the well,
respectively). The biofilm-laden peg lids were placed in the
antibiotics and incubated at 35 °C on a rocking table. After 48 h of
exposure to antibiotics, the peg lids were rinsed in sterile broth,
placed in a fresh microtitre plate, and sonicated for 5 min to
remove the biofilm. The peg lid was discarded and the plate with
the sonicated bacteria was incubated overnight. The following
day, the wells were examined for turbidity. If there was no growth
in the well, the antibiotic combination was assumed to have
eradicated the biofilm.
3.1. Analysis
Statistical analysis was done using SAS version 9. Con-
tinuous variables were analyzed by independent t test. The
proportion of treatment failures was compared using an un-
adjusted Fisher exact test. Kaplan-Meier survival curves were
used to describe time to next exacerbation.
In addition, linear regression procedures were employed to
adjust continuous outcomes for imbalances in infection rates
with B. cepacia or A xylosoxidans between the two groups.
Hazard ratios for time to next exacerbation were also computed
using Cox proportional hazards models with adjustment for B.
cepacia and A. xylosoxidans infection.
4. Results
One hundred and thirty-two patients had been included in the
original clinical trial however 22 of these patients were not
included in the current study for the following reasons: their
isolates were not frozen for storage (13 patients), their isolates
were missing (3 patients), or their frozen isolates did not grow
when thawed (6 patients). The remaining 110 patients had the
original bacterial isolates from the time of their pulmonary
exacerbation available for biofilm susceptibility testing, and
these patients were included in the current study.
Two hundred thirty-four bacterial isolates from these 110
patients with acute CF pulmonary exacerbations were analyzed.
Biofilm growth controls (tested in the absence of antibiotics)were positive for each of these isolates, suggesting that all of
these isolates were able to successfully grow in-vitro as bac-
terial biofilms.
When the bacterial isolates were grown planktonically as
part of the original trial, 66 of the 110 patients (60%) included in
the current study were treated with antibiotic combinations that
inhibited all of their planktonically-grown bacterial isolates.
However, when the bacteria were grown as a biofilm, only 24
patients (22%) had all of their biofilm-grown isolates remaining
susceptible to the antibiotics (P=b0.001 ). Sixty-one patients
(55%) were treated with intravenous antibiotic combinations
that inhibited at least one of the biofilm-grown bacterial isolates
retrieved at exacerbation.
Clinical outcomes for the patients in whom at least one
biofilm-grown isolate was susceptible to the received antibiotic
combination (n=61 patients, 154 isolates) were compared to
patients in whom none were susceptible (n=49 patients, 80
isolates). The baseline characteristics for these patients are listed
in Table 1. The antibiotic combinations most commonly re-
ceived by the patients are listed in Table 2. There was a sig-
nificant decrease in bacterial density after 2 weeks of antibiotic
treatment (P=0.02) in the patients in whom at least one isolate
was susceptible compared to those with no susceptible isolates
(Table 3). These patients had a shorter mean hospital length of
stay (13.3 days vs. 17.4 days, P=0.04). The treatment failure
rate was 3.2% (2/61 patients) in those with at least one biofilm-
grown susceptible isolate, compared to 12.2% (6/49 patients) in
those with no susceptible isolates, although this difference did
Table 2
Antibiotic combinations most commonly received by patients in whom at least
one biofilm-grown isolate was susceptible and patients in whom no biofilm-
grown isolates were susceptible
Antibiotic combinations At least one
biofilm-grown isolate
susceptible (n=61)
No biofilm-grown
isolates susceptible
(n=49)
Tobramycin+meropenem 17 (28%) 13 (27%)
Tobramycin+ceftazidime 4 (7%) 8 (16%)
Piperacillin-tazobactam+
ceftazidime
4 (7%) 6 (12%)
Ciprofloxacin+ceftazidime 4 (7%) 5 (10%)
Ciprofloxacin+meropenem 7 (11%) 1 (2%)
Ceftazidime+meropenem 6 (10%) 1 (2%)
Trimethoprim-sulfamethoxazole+
meropenem
4 (7%) 2 (4%)
Piperacillin-tazobactam+
meropenem
5 (8%) 1 (2%)
Inhaled tobramycin as third
antibiotic
51 (84%) 29 (59%)
Table 4
Changes in lung function, dyspnea, hospital length of stay, treatment failure
rates and sputum bacterial density in patients in whom all biofilm-grown isolates
were susceptible compared to patients in whom at least one biofilm-grown
isolate was not susceptible
All biofilm-
grown isolates
susceptible
(n=24)
At least one
biofilm-grown
isolate not
susceptible (n=86)
P-Value
Mean change in sputum
bacterial density from day 0
to 14 in CFU/ml
−3.82×107 −3.96×107 0.94
Changes in FEV1 in L, day 0 to
14 (SD)
0.35 (0.27) 0.22 (0.38) 0.18
Changes in FVC in L, day 0 to
14 (SD)
0.54 (0.39) 0.35 (0.46) 0.11
Transitional Dyspnea Index
score, day 14 (SD)
6.95 (2.66) 5.61 (3.96) 0.06
Treatment failure rates (%) 2/24 (8.3) 6/86 (7.0) 1.00
Patients infected with
B. cepacia or A xylosoxidans
1/10 4/46 1.00
Patients not infected with
B. cepacia and A. xylosoxidans
1/14 2/40 1.00
Mean hospital length of stay in
days (SD)
14.7 (9.5) 15.4 (9.4) 0.74
125T. Keays et al. / Journal of Cystic Fibrosis 8 (2009) 122–127not reach statistical significance (P=0.14). Changes in FEV1
and FVC, as well as the change in Transitional Dyspnea Index,
were similar in the two groups (Table 3).
When patients in whom all biofilm-grown isolates were
susceptible to the received antibiotic combination (n=24
patients, 46 isolates) were compared to those in whom at least
one of the isolates was not susceptible (n=86 patients, 188
isolates), the groups did not have statistically different mean
changes in sputum bacterial density or length of stay (Table 4).
However, patients in whom all biofilm-grown isolates were
susceptible to their received antibiotic combination tended to
have improved lung function (FEV1 and FVC) and better
dyspnea scores after 14 days of antibiotic therapy, although
these results fell slightly short of statistical significance.
Statistical analyses which adjusted for baseline imbalances in
infection with B. cepacia or A xylosoxidans did not appreciably
affect the results for any of the continuous outcome variables. ForTable 3
Changes in lung function, dyspnea, hospital length of stay, treatment failure rates
and sputum bacterial density in patients in whom at least one biofilm-grown
isolate was susceptible compared to patients in whom no biofilm-grown isolates
were susceptible
At least one
biofilm-grown
isolate susceptible
(n=61)
No biofilm-
grown isolates
susceptible
(n=49)
P-value
Mean change in sputum bacterial
density from day 0 to 14 in
CFU/ml
−6.26×107 −1.50×107 0.02
Changes in FEV1 in L, day 0 to 14 0.26 (0.38) 0.23 (0.35) 0.73
Changes in FVC in L, day 0 to 14 0.39 (0.46) 0.38 (0.45) 0.85
Transitional Dyspnea Index
score, day 14
6.36 (3.49) 5.31 (4.03) 0.15
Treatment failure rates (%) 2/61 (3.2) 6/49 (12.2) 0.14
Patients infected with B. cepacia
or A xylosoxidans
1/24 4/32 0.38
Patients not infected with
B. cepacia and A xylosoxidans
1/37 2/17 0.23
Mean hospital length of stay in days 13.3 (6.9) 17.4 (11.3) 0.04instance, the mean unadjusted difference in length of hospital stay
for patients in whom at least one biofilm-grown bacterial isolate
was susceptible to the received antibiotics compared to those with
no susceptible isolates, was 4.3 days, and the mean adjusted
difference in length of stay was 4.1 days (P=0.04, for both the
adjusted and the unadjusted comparisons). Similarly, the mean
unadjusted difference in FEV1 was 0.03 L, and the mean adjusted
difference in FEV1 was 0.01 L (P=0.73 and 0.93, respectively).
Survival analyses of the time to next exacerbation using
Kaplan-Meier curves showed non-significant trends in both
groups favoring patients treated with antibiotics that inhibited
their biofilm-grown airway bacteria. The hazard ratio was 0.88 for
at least one isolate susceptible compared to no isolates susceptible
(95%CI 0.60–1.29, P=0.51) and the hazard ratio was 0.75 for all
isolates susceptible compared to not all isolates susceptible (95%
CI .47–1.20, P=0.23) (Fig. 1).When the survival analysis was
adjusted for infection with B. cepacia or A xylosoxidans, the
trend to prolonged time to next exacerbationwas further enhanced
for the groups treated with antibiotics that inhibited their biofilm-
grown airway bacteria. The adjusted hazard ratios decreased from
0.88 to 0.76 (adjusted P=0.21) and from 0.75 to 0.69 (adjusted
P=0.13), respectively.
5. Discussion
This study is the first in the literature to examine the effect of
antibiotic therapy directed against biofilm-grown bacteria on
clinical outcomes in CF patients with pulmonary exacerbation.
Perhaps the most important finding is that only a minority of CF
patients treated for pulmonary exacerbation with antibiotics
chosen based on susceptibility testing of planktonically-grown
bacteria, actually received antibiotics that were effective against
their same sputum bacteria grown as biofilms. This finding
Fig. 1. Kaplan-Meier estimates of the probability of remaining exacerbation-free in patients in whom all biofilm-grown isolates were susceptible compared to not all
isolates susceptible. Censored observations represent the four patients who did not have a next exacerbation during the study period .They were followed until the end
of the study and were censored in the survival analysis at the point when the study follow-up ended.
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antibiotics effective against biofilm-grown bacteria using con-
ventional planktonic culturing techniques.
Why is it important to use biofilm-effective antibiotics in
treating CF exacerbations? Increasing evidence supports the
hypothesis that bacteria grow as biofilms within the lungs of
CF patients. Using transmission electron microscopy, biofilm
colonies of Pseudomonas aeruginosa have been observed in
CF sputum [7]. Pathologic studies have also shown Pseudo-
monas bacteria existing in biofilm colonies within the small
airways of CF lungs [16]. Furthermore, antibiotic resistance is
increased when susceptibility testing is done on bacteria grown
as biofilms. Other studies of CF patients have shown that
biofilm-grown organisms are less susceptible to single or com-
binations of antibiotics than planktonically grown organisms
from the sputum of CF patients infected with both Pseudomo-
nas aeruginosa [8,9] and Burkholderia cepacia [17]. This was
confirmed by our current study where 60% of the treated
patients had all of their planktonically-grown bacterial isolates
susceptible to the received antiobitics but only 22% had all of
the same isolates susceptible when they were grown as biofilms.
It has also been shown that the biofilm inhibitory concentrations
are much higher than the corresponding conventionally de-
termined minimum inhibitory concentrations (MIC) for many
antibiotics used in CF [9]. Therefore, CF patients may require
different combinations of antibiotics than suggested by con-
ventional planktonic susceptibility testing to achieve inhibitory
activity against the biofilm-forming bacteria in their airways.
Another question is whether treating CF patients with anti-
biotics that are effective against the bacterial biofilm will result
in improvements in clinical outcomes from pulmonary exacer-
bations. The evidence suggests that there is little correlation
between conventional in-vitro antibiotic susceptibility testing ofplanktonically-grown bacteria and clinical response to anti-
biotics in CF pulmonary exacerbations [18]. By growing the
bacteria as biofilms in vitro prior to antibiotic susceptibility
testing, we may more closely mimic in vivo bacterial growth
and therefore select antibiotics with better activity against the
bacteria growing within the airways of CF patients.
The biofilm culture technique used in our study has been
previously validated by other groups [15]. In addition, we
previously showed that combination antibiotic biofilm sus-
ceptibility testing is reproducible over time when biofilm-
grown isolates were frozen, thawed, and then re-tested
8 weeks later [8]. In the current study, all growth controls
were positive indicating that each isolate was able to be grown
as a biofilm.
The patients in this study who were treated with antibiotics
that inhibited biofilm growth of at least one sputum isolate
showed significant improvement in sputum bacterial density
and length of hospital stay (Table 1). The other clinical variables
examined, although not achieving statistical significance,
showed trends toward improved clinical outcomes in those
treated with antibiotics effective against their biofilm-grown
bacteria. One possible explanation for the trends toward im-
proved clinical outcomes in patients treated with biofilm-ef-
fective therapy is that these patients were infected with less
resistant organisms and therefore would have improved clinical
outcomes regardless of antiobiotic choice. However, when the
continuous outcomes were adjusted for infection with Bur-
kholderia cepacia and/or Achromobacter xylosoxidans, bacteria
which are typically more resistant to antibiotics, there were no
significant changes to the results.
Obviously failure to show statistical significance for all of
the evaluated clinical outcomes limits our ability to make de-
finitive conclusions regarding efficacy of biofilm-directed
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antibiotics that inhibited all biofilm-grown isolates retrieved at
exacerbation was relatively small (n=24). Therefore, compar-
isons using this small group of patients may be limited by lack
of power, and this may explain why comparisons involving this
group yield P values that fall short of statistical significance.
Other limitations of this study include its retrospective
design. There may be confounding variables associated with
biofilm-effective therapy that were not accounted for and may
influence clinical response to therapy. For example, a higher
percentage of patients who received triple antibiotic therapy in
the form of inhaled tobramycin added to two intravenous anti-
biotics had at least one biofilm-grown isolate that was sus-
ceptible to the antibiotics (Table 2). If inhaled tobramycin has
greater activity against biofilm-grown bacteria, and if use of
inhaled tobramycin is associated with improved clinical out-
comes in CF exacerbation independent of its anti-biofilm prop-
erties, then this could also potentially confound our data.
This was not a prospective randomized controlled trial com-
paring biofilm culturing techniques to conventional planktonic
culturing techniques. Antibiotic combinations were prescribed
according to results of either conventional or combination
antibiotic susceptibility testing on planktonic bacterial cultures,
not according to the results of biofilm susceptibility testing. The
patients were then regrouped based on retrospective results
from their biofilm cultures. Thus, this study is hypothesis-gen-
erating, and should be used to spur development of future
prospective trials.
Although the retrospective study design limits definitive
conclusions, patients with CF exacerbations who were treated
with antibiotic combinations that were effective against their
biofilm-grown bacteria seemed to have improved clinical out-
comes. Future research is needed in the form of a prospective
trial comparing clinical outcomes in CF patients randomized to
conventional susceptibility testing compared to biofilm suscept-
ibility testing, to determine if antibiotic treatment based on
biofilm susceptibility testing leads to improved clinical out-
comes for patients with CF pulmonary exacerbations.
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